Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial.
Related Research units
Abstract
Dolutegravir (S/GSK1349572) is a new HIV-1 integrase inhibitor that has antiviral activity with once daily, unboosted dosing. SPRING-1 is an ongoing study designed to select a dose for phase 3 assessment. We present data from preplanned primary and interim analyses.
Bibliographical data
| Original language | English |
|---|---|
| Article number | 2 |
| ISSN | 1473-3099 |
| Publication status | Published - 2012 |
| pubmed | 22018760 |
|---|
